Angiopoietin-2 (Ang2) exhibits broad expression in the remodeling vasculature of human tumors but very limited expression in normal tissues, making it an attractive candidate target for antiangiogenic cancer therapy. To investigate the functional consequences of blocking Ang2 activity, we generated antibodies and peptide-Fc fusion proteins that potently and selectively neutralize the interaction between Ang2 and its receptor, Tie2. Systemic treatment of tumor-bearing mice with these Ang2-blocking agents resulted in tumor stasis, followed by elimination of all measurable tumor in a subset of animals. These effects were accompanied by reduced endothelial cell proliferation, consistent with an antiangiogenic therapeutic mechanism. Anti-Ang2 therapy also prevented VEGF-stimulated neovascularization in a rat corneal model of angiogenesis. These results imply that specific Ang2 inhibition may represent an effective antiangiogenic strategy for treating patients with solid tumors.
Introduction
cancer therapy, such as drug resistance and inadequate drug delivery, might be averted. Promising results have been obConventional cancer therapies often fail to control disease and served in clinical trials employing such agents (Hurwitz et al. , are toxic by design. To avoid these drawbacks, pharmaceutical 2003; Kabbinavar et al., 2003; Raymond et al., 2002 ; Yang et efforts are increasingly focusing on therapies that target molecual., 2002) , particularly with drugs targeting the VEGF-VEGFR lar abnormalities specific to tumorigenesis. While some success pathway, such as Bevacizumab (a humanized VEGF-A binding has been achieved with such targeted drugs (e.g., STI571, Rituxantibody that was recently approved for the treatment of colon imab, Trastuzumab, Gefitinib, and Erbitux), none of the commercancer) and SU11248 (a small molecule that inhibits the activity cially approved targeted therapies is capable of treating broad of several protein kinases, including KDR, a VEGF receptor). populations of cancer patients (Rothenberg et al., 2003) . MoreNonetheless, clinical efficacy has been mixed for drugs targeting over, while the targeted therapies are generally less toxic than the VEGFs or their receptors (Anonymous, 2002; Miller et al., conventional cancer therapies, clinical safety issues have been 2002; Zangari et al., 2004) , and significant toxicities have been noted for these drugs. It has been proposed that antiangiogenic observed, including fatigue, headaches, hypertension, clotting cancer therapy might be more broadly effective and safer than abnormalities, and life-threatening hemorrhages (DeVore et al., either targeted or traditional therapies aimed at cancer cells 2000; Kabbinavar et al., 2003; Miller et al., 2002) . (Folkman, 1998) . Moreover, because antiangiogenic therapy is While the VEGFs and their receptors have been among the designed to target blood vessels perfusing tumors, rather than most extensively targeted molecules in the angiogenesis field, preclinical efforts targeting the more recently discovered angiotumor cells themselves, traditional impediments to successful
S I G N I F I C A N C E
It has been proposed that therapies targeting the tumor vasculature may be more broadly efficacious and less toxic than conventional cancer treatments. Rational design of such therapies involves the identification and characterization of candidate drug targets whose functions are largely restricted to the process of angiogenesis. Ang2, a secreted factor whose expression is upregulated at sites of angiogenesis, holds promise as one such candidate. To evaluate the in vivo effects of Ang2 neutralization, we have developed Ang2-selective inhibitors. Systemic anti-Ang2 therapy inhibited tumor growth and angiogenesis in preclinical pharmacology models, and it was well tolerated. Whether Ang2-selective inhibitors will mediate similar effects in humans awaits the evaluation of these therapies in clinical trials. poietin-Tie2 pathway are now gaining strength (Qian et al., or Ang2 are playing pro-and/or antiangiogenic roles in this context. Bolstering the hypothesis that Ang2 is proangiogenic, 2002). Both protein families involve ligand-receptor interactions, Ang2 knockout mice display early postnatal vascular remodeling and both include members whose functions are largely redefects in the eye , as stricted postnatally to endothelial cells (and some hematopoietic well as developmental lymphatic defects; curiously, the latter stem cell lineages [Iwama et al., 1993] ) by virtue of the selective deficiency, but not the former, can be rescued by replacing the expression of their respective receptors on those cell types Ang2 gene with the Ang1 gene. Blocking angiopoietin function (Gale and Yancopoulos, 1999; Mustonen and Alitalo, 1995) . Tie2 pharmacologically in a postnatal setting by sequestration with is a receptor tyrosine kinase with four known ligands, angiopoiea soluble Tie2 receptor has been shown to have an inhibitory tin-1 (Ang1) through angiopoietin-4 (Ang4), the best studied effect on tumorigenesis and neovascularization (Das et al., 2003; being Ang1 and Ang2 (Gale and Yancopoulos, 1999) . Whereas Hangai et al., 2001b; Lin et al., 1997 Lin et al., , 1998 ; Siemeister et al., Ang1 clearly stimulates phosphorylation of Tie2, Ang2 interac-1999) . However, given that all four angiopoietins bind to Tie2, tion with Tie2 has been shown to both antagonize and agonize it is not clear whether this effect was mediated by inhibition of Tie2 receptor phosphorylation, under varying conditions (Davis Ang1, Ang2, Ang3, Ang4, or a combination thereof. To enable et al., 1996; Kim et al., 2000; Maisonpierre et al., 1997 ; Mochizuki a more definitive evaluation of postnatal Ang2 function, we have et Teichert-Kuliszewska et al., 2001) . The phenotypes generated agents capable of selectively neutralizing the activity of mouse Tie2 and Ang1 knockouts are similar and suggest that of this factor. Here, we show that systemic administration of Ang1-stimulated Tie2 phosphorylation mediates both remodelthese Ang2-selective inhibitors is sufficient to suppress both ing and stabilization of developing vessels in utero through tumor angiogenesis and corneal angiogenesis, thus supporting maintenance of endothelial cell:support cell adhesion (Dumont the notion that Ang2 plays a proangiogenic role postnatally. et al., 1994; Sato et al., 1995; Suri et al., 1996) . The role of Ang1 in vessel stabilization is thought to be conserved in the adult, Results where the gene is expressed widely and constitutively (Hanahan, 1997; Zagzag et al., 1999) . In contrast, normal postnatal Ang2
CANCER CELL
Identification and characterization expression is highest at sites of vascular remodeling (ovary, of Ang2-selective inhibitors placenta, and uterus), where it has been proposed to block Two types of Ang2-selective inhibitors, peptide-Fc fusion proAng1 function, thereby inducing a state of vascular plasticity teins and antibodies, were generated as reagents to interrogate conducive to angiogenesis (Hanahan, 1997; Holash et al., 1999;  angiopoietin function (Supplemental Experimental Procedures Maisonpierre et al., 1997). Vessel-selective Ang2 induction has at http://www.cancercell.org/cgi/content/full/6/4/507/DC1/). Phage also been demonstrated in disease states associated with andisplay peptide and Fab libraries were panned against human giogenesis. These pathological conditions include cancer, macAng2, and the resulting Ang2 binding clones were converted into ular degeneration, rheumatoid arthritis, osteoarthritis, and psoripeptide-Fc fusion proteins (by expressing the active peptides in asis (Bunone et al., 1999; Etoh et al., 2001; Fearon et al., 2003;  E. coli as fusions to the Fc portion of human IgG1) or fully human Hangai et al., 2001a; Holash et al., 1999; Kuroda et al., 2001;  antibodies (by expressing the active Fabs in CHO cells on a Otani et al., 1999; Shahrara et al., 2002; Stratmann et al., 1998;  complete IgG1 framework). Peptide-Fc fusion proteins and anti- Tanaka et al., 1999; Yoshida et al., 1999; Yuan et al., 2000;  bodies were then screened by ELISA for their ability to neutralize Zagzag et al., 1999) .
the interaction between Tie2 and angiopoietins. A subset of the Elevated Ang2 expression at sites of normal and pathologipeptide-Fc fusion proteins were affinity-matured to enhance cal postnatal angiogenesis circumstantially implies a proangiotheir ability to neutralize Ang2. Two peptide-Fc fusion proteins genic role for Ang2 (Maisonpierre et al., 1997) . However, experi-(2xCon4 (C) and L1-7 (N)) and one antibody (Ab536) were chosen ments designed to functionally confirm this conclusion have for further study, based on their ability to potently neutralize the yielded ambiguous and contradictory results. For example, echuman Ang2:human Tie2 interaction (IC 50 values of 23, 54, and topic expression of Ang2 in cancer cells has been shown to 140 pM, respectively [ Table 1A] ). All three reagents exhibited promote tumor growth and vascularization in xenograft and similar IC 50 values against Ang2 from other species (Table 1A) , chorioallantoic membrane angiogenesis models (Ahmad et al., enabling their evaluation in preclinical pharmacology models. Etoh et al., 2001; Tanaka et al., 1999) . In contrast, Ang2
Furthermore, the three inhibitors exhibited between 30-fold overexpression has also been reported to inhibit both local tuand Ͼ4500-fold selectivity for Ang2 over other angiopoietin mor growth and metastasis and thereby prolong the survival of family members (Table 1A) . Human IgG1 Fc alone exhibited no mice injected with these tumors (Yu and Stamenkovic, 2001) .
angiopoietin-neutralizing activity in this ELISA. None of these Experiments using transgenic mice ectopically expressing four agents had activity in a VEGF-VEGFR neutralization assay VEGF, Ang1, and Ang2 in cardiac muscle have demonstrated (Table 1A) , whereas Bevacizumab inhibited this interaction with that Ang2 stimulates VEGF-mediated angiogenesis, whereas an IC 50 of 2 nM (data not shown). Ang1 suppresses it (Visconti et al., 2002) . Further supporting To determine practical dosing frequencies and routes of the hypothesis that Ang1 and Ang2 play mutually antagonistic administration for Ang2-blocking agents, pharmacokinetic proroles in developmental vascular remodeling, Ang2 transgenic files were generated in rodents for 2xCon4 (C), L1-7 (N), and mice (in which Ang2 expression is driven by the Tie2 promoter) Ab536 (Table 1B and Supplemental Experimental Procedures). and Ang1 knockout mice share a similar phenotype, consisting
The resulting pharmacokinetic parameters supported the feasiof defective vascular patterning, vessel discontinuity, and debility of daily to weekly subcutaneous dosing. tachment of the endocardium from the myocardium (Maisonpierre et al., 1997) . But since this phenotype implies defects Ang2 antagonism inhibits tumor growth in both vascular remodeling and stabilization, two seemingly
To evaluate the effect of Ang2 inactivation on tumor growth, nude mice bearing subcutaneous A431 human epidermoid tucontradictory processes, it remains unclear whether either Ang1 A: Peptide-Fc fusion proteins, antibody, and human IgG1 Fc were evaluated by ELISA for their ability to neutralize angiopoietin:Tie2 interactions. Candidate inhibitory agents were titrated from 100 nM to 0.4 pM in the presence of 1 nM Tie2 and subsequently added to a panel of angiopoietins. The degree of angiopoietin:Tie2 neutralization (IC 50 ) was determined by comparison against a Tie2 standard curve (the binding activity of serially diluted Tie2 in the absence of competitor). As an additional control for specificity, Ang2-inhibitory agents were also tested in an analogous fashion for their ability to neutralize the hVEGF:KDR interaction (last column of table). Bevacizumab (a neutralizing anti-hVEGF antibody) displayed a 2.1 nM IC 50 in this assay (data not shown). B: Pharmacokinetic parameters of Ang2 inhibitors in mice and rats. Terminal half-lives (t 1/2 ) and areas under the serum concentration-time curves from time 0 to infinity (AUC inf ) are shown. AUC inf values were normalized to a 1 mg/kg dose. a t 1/2 and AUC inf were calculated from the composite mean serum concentration-time data, n ϭ 2-3/time point. b t 1/2 and AUC inf were calculated from the mean serum concentration-time data of 6 mice or 3 rats.
mor xenografts were treated with a range of Ab536 dose levels that the effects of Ab536 on tumor growth in vivo were conferred indirectly through an antiangiogenic mechanism, rather than (thrice weekly) beginning 3 days after tumor challenge ( Figure  1A ). A431 xenografts, like other tumor models, display vesselthrough a direct effect on tumor cells. We next sought to determine whether the tumor growth selective Ang2 expression ( Figure 1C and Supplemental Experimental Procedures). Ab536 significantly inhibited tumor growth inhibition observed in the A431 model could be reproduced in other tumor models. Administration of 2xCon4 (C), L1-7 (N), or relative to control IgG when dosed at 2 and 6 mg/kg, but not at lower dose levels ( Figure 1A) . A longer-term study employing Ab536 to mice bearing subcutaneous Colo205 human colorectal tumor xenografts resulted in tumor growth inhibition, indicating Ab536 at 2 mg/kg (the optimal biological dose) showed more dramatic inhibition of tumor growth ( Figure 1B ). Ab536, as well that the observed antitumor effects were not cancer type specific or reagent specific ( Figure 2A ). Vascular Ang2 expression as the other Ang2 inhibitors, failed to suppress the growth of cultured A431 cells ( Figure 1D ), consistent with the hypothesis was confirmed by in situ hybridization ( Figure 2B and Supple- mental Experimental Procedures). Ang2 inhibition was shown Even more dramatic regression, apparent even by gross external measurements, was observed when the initiation of to mediate similar tumor growth inhibition in the HT29 xenograft model (Supplemental Figure S1) . therapy was further delayed, and this regression appeared to be reversible following serum clearance of the Ang2-neutralizing Two additional Colo205 tumor xenograft experiments were performed to evaluate peptide-Fc fusion protein dose-response agent ( Figure 5 ). In this experiment, 2xCon4 (C) was administered on either a twice weekly schedule (0.6 mg/kg) starting relationships. Twice weekly administration of 0.6 or 15 mg/kg 2xCon4 (C) yielded equivalent levels of tumor growth inhibition on Day 21 ("narrow-interval dosing") or in individual doses (25 mg/kg) on Days 45 and 116 ("wide-interval dosing"). Dosing on ( Figure 3A ), whereas dosing of 0.12 or 0.024 mg/kg 2xCon4 (C) on the same schedule resulted in a progressive reduction in a wide interval allowed 2xCon4 (C) to be cleared from the serum between doses. Rapid tumor regression was observed in the effect relative to the 0.6 mg/kg dose ( Figure 3B ). The same optimal biological dose of 0.6 mg/kg twice weekly was observed wide-interval group following the Day 45 dose. This regression was sustained until Day 69, at which point tumor regrowth began with L1-7 (N) (data not shown).
In the tumor xenograft studies discussed thus far, dosing to occur, suggesting that 2xCon4 (C) exposure had fallen below effective levels. Resumption of dosing on Day 116 resulted again began 3 days after tumor cells were injected. To better replicate conditions of established disease, Colo205 tumors were alin tumor regression, indicating that tumors had not acquired resistance to anti-Ang2 therapy. While this study showed reverslowed to grow for 28 days before 2xCon4 (C) dosing was initiated ( Figure 4A ). A separation in growth rates between the vehiibility of the treatment-mediated antitumor effect, growth inhibition was not observed to be reversible in experiments in which cle and treated groups could be observed within 3 days of treatment initiation, and the gross tumor volume of the treatment dosing was initiated by experimental Day 28 (data not shown).
To further evaluate the long-term effects of Ang2 inhibition group remained static over the 21 days of therapy, indicating that anti-Ang2 therapy could inhibit the growth of established on tumor growth, several groups of animals harboring A431 and Colo205 tumor xenografts were treated continuously with tumors. To examine drug effects at the histological level, cohorts of animals in this study were sacrificed weekly for tumor evalua2xCon4 (C) or Ab536 for at least 10 weeks (Supplemental Table  S1 and Supplemental Experimental Procedures). Although varition. A progressive reduction in viable tumor fraction was observed in the treatment group relative to the vehicle group (Fig- ous dosing levels and schedules were employed, all were predicted to result in serum trough levels exceeding the exposure ures 4B-4D and Supplemental Experimental Procedures), indicating that volume-based tumor measurements, which fail required for optimal effect. In 13 of 15 groups, anti-Ang2 therapy eliminated all measurable tumor in a subset of animals. In three to distinguish viable tumor from necrotic tissue, underestimated peptide-Fc fusion protein-mediated antitumor effects. Thus, of these groups, drug was withdrawn after the complete responses were achieved, and no tumor regrowth was observed anti-Ang2 treatment mediated regression of viable tumor. A: 2xCon4 (C) dose levels of 15 and 0.6 mg/kg (twice weekly) had similar antitumor effects to one another and to Ab536 dosed at 2 mg/kg (thrice weekly). B: Reducing the 2xCon4 (C) doses levels to 0.6, 0.12, and 0.024 mg/kg (twice weekly) resulted in a clear dose-response effect. While maximal effect was observed with 0.6 mg/kg, a partial inhibitory effect was observed with the intermediate dose of 0.12 mg/kg. The low dose of 0.024 mg/kg was ineffective. in these animals (average follow-up 15.3 weeks; range 6-27 systems attributable to Ang2 neutralization (Supplemental Exweeks).
perimental Procedures). The 2xCon4 (C) protein had no signifiUpon completion of tumor xenograft studies, mice were cant adverse effects on xenograft-bearing mice when dosed sacrificed to search for possible adverse effects in major organ either at 14 mg/kg twice per week for 11 weeks (monitoring hematology values, serum chemistry values, or histology) or 8 mg/kg daily for 11 weeks (monitoring organ weights and histology). Similarly, L1-7 (N) had no untoward effects on any of the endpoints evaluated (hematology values, serum chemistry, or histology) in xenograft-bearing mice when dosed at 14 mg/kg twice per week for 7 weeks.
Ang2 inhibition suppresses the proliferation of tumor endothelial cells
To begin investigating the mechanism through which Ang2 neutralization mediates tumor growth inhibition, Colo205 xenografts from mice treated with 2xCon4 (C) or vehicle were evaluated at the cellular level. FACS analysis revealed that 2xCon4 (C) treatment resulted in a progressive reduction in endothelial cell proliferation, followed by a reduction in tumor cell proliferation ( Figure 6A and Supplemental Experimental Procedures), sug- cell proliferation, 72 hr of 2xCon4 (C) treatment was required
The other group was treated with vehicle until Day 44 and then with to achieve a reduction in tumor cell proliferation that deviated 25 mg/kg doses of 2xCon4 (C) on Days 45 and 116 ("Wide-Interval Dosing" group).
below the aggregate mean tumor cell proliferation of all vehicle- treated groups (tumor cell proliferation in the vehicle-treated was well tolerated and revealed no significant adverse effects (Supplemental Experimental Procedures). A pharmacological groups remained relatively constant over time). Additional analyses by histological methods demonstrated that 2xCon4 (C) ineffect on epiphyseal growth plate thickness was observed in male 2xCon4 (C)-treated rats dosed at 75 mg/kg (2 of 3 rats) duced tumor cell apoptosis in Colo205 xenografts ( Figure 6B ), an effect that is consistent with the reduced viable tumor fraction and 200 mg/kg (3 of 3 rats). No growth plate abnormalities were observed in identically treated rats that were subsequently observed in 2xCon4 (C)-treated mice ( Figures 4B-4D ). The temporal and causative relationships between 2xCon4 (C)'s effects withdrawn from drug for 1 month, suggesting that these effects on tumor cell proliferation and apoptosis are not yet known.
were reversible. Epiphyseal plate thickening is considered to be a pharmacological consequence of antiangiogenic therapy Direct antiangiogenic effect mediated and has been seen in growing rodents treated with VEGF-neuby Ang2 neutralization tralizing antibodies (Gerber et al., 1999) . This phenomenon We next sought further support for the hypothesis that antiwould not be expected to occur in adult animals treated with Ang2 therapy mediates a direct antineovascular effect in vivo.
antiangiogenic agents, as endochondral bone formation is comThe rat corneal angiogenesis model was chosen for this purpleted before adulthood. Also of note, a multifocal infiltration pose, as it allows neovascularization to be studied outside the of mononuclear cells was seen on the exterior surface of the context of tumorigenesis. In this model, a VEGF-soaked nylon splenic capsule in some treated rodents, but not primates (data disk is placed in the normally avascular cornea at a fixed disnot shown). The finding had no known functional consequences, tance from the surrounding limbal vessels. Neovessels subseand its etiology is under investigation. Together, the accumuquently sprout from the limbal vessels toward the developing lated preclinical pharmacology data support the conclusion that VEGF gradient. In situ hybridization (ISH) was used to demonAng2 inactivation suppresses angiogenesis in both neoplastic strate that Ang2 was expressed in the VEGF-induced corneal and nonneoplastic settings, without untoward effects on animal neovasculature (Supplemental Figure S2 and Supplemental Exhealth. perimental Procedures). Ang2 mRNA levels were shown to be upregulated during VEGF-induced corneal angiogenesis in a Discussion punctate pattern similar to that observed in tumor vessels. Ang2 ISH signal was identified only in neovessels sprouting from the Previous work in this field has highlighted the complexity of Ang2 function. In vitro and in vivo experiments have suggested limbus, and no signal could be observed in the absence of exogenous VEGF stimulation. The consequences of inactivating that Ang2 can either agonize or antagonize (Davis et al., 1996; Kim et al., 2000; Maisonpierre et al., 1997; Mochizuki et al., 2002 ; Ang2 in this model were then evaluated. Systemic administration of 2xCon4 (C) over a range of 0.125 to 4 mg/kg twice weekly Teichert-Kuliszewska et al., 2001 ) the Tie2 receptor, depending on context. Ang2 has been shown to play opposing roles at the resulted in a dose-dependent inhibition of VEGF-mediated corneal angiogenesis ( Figure 7A ), with reduction of angiogenesis cellular and organismal levels as well, promoting either vascular sprouting or regression, depending on whether VEGF is present to negative control levels observed at the 1 mg/kg dose level. L1-7 (N) and Ab536 were also shown to inhibit corneal angiogen- (Maisonpierre et al., 1997) . The phenotype of the recently published Ang2 knockout mouse is informative in that it convincingly esis to background levels ( Figure 7B ), further demonstrating that the effects of anti-Ang2 therapy were not reagent specific.
implicates Ang2 as a required factor for early postnatal retinal neovascularization . HowTreatment of rats with L1-7 (N) and 2xCon4 (C) at subcutaneous doses as high as 200 mg/kg twice weekly for 2 weeks ever, these studies also highlight the context-dependent nature Angiogenesis was induced by implanting VEGFor BSA-soaked nylon discs into the corneal stroma of female CD rats. Treatment with 2xCon4(C) (A), Fc control or L1-7(N) (B) was initiated 1 week prior to corneal implantation and continued twice per week. Animals receiving Ab536 (B) were injected on the day of surgery and three days later. For all groups, angiogenesis was evaluated 1 week after disc implantation. Values are the group mean Ϯ standard error of the mean (n ϭ 8). *p Ͻ 0.02.
of Ang2 dependency in angiogenesis; Ang2 was shown in these phenotype , in which no prenatal vascular defects were observed, despite strong embryonic expression same experiments to be dispensable for developmental neovascularization and for pathological angiogenesis in the abnormally of Ang2 in and around large vessels in wild-type mice. Thus, expression of Ang2 does not necessarily confer functional deretained hyaloid vasculature of rare knockout mice surviving to day 25 . In tumor models, ectopic Ang2 pendence on this factor. Nonetheless, additional studies of longer duration and in the context of other angiogenesis-associexpression has been shown to both stimulate and inhibit tumor growth and tumor angiogenesis, thus adding to the confusion ated processes (such as wound healing and estrous cycling) would be necessary to fully assess the effects of Ang2-neutralizregarding Ang2 function. The only published attempt to selectively neutralize Ang2 in vivo using a pharmacological agent (an ing agents. While this study sheds light on Ang2 biology and the thera-RNA aptamer) resulted in incomplete angiogenic inhibition, even in the context of local administration, thus leaving unanswered peutic implications of Ang2 inhibition, it also stimulates additional questions. First, the cellular and molecular consequences the question of whether Ang2 inhibition alone is sufficient to fully inhibit angiogenesis (White et al., 2003) . The cellular mechanism of Ang2 neutralization require further investigation. It remains to be determined, for example, how Ang2 neutralization blocks through which selective Ang2 inhibition mediated angiogenic suppression also remains to be addressed. Panangiopoietin endothelial cell proliferation, if it alters pericyte/cell matrix coverage of capillaries, or how it might alter tumor perfusion. Of inhibition (with soluble Tie2) has also been shown to mediate suppression of tumor growth and angiogenesis, but none of note, ectopically administered Ang2 has been shown to promote endothelial cell proliferation and sprouting of new blood vessels these effects can be attributed specifically to Ang2 inactivation (Das et al., 2003; Hangai et al., 2001b; Lin et al., 1997 Lin et al., , 1998  in the papillary membrane of the eye, and these effects were associated with increased capillary diameter, basal lamina reSiemeister et al. , 1999) . It therefore remains unclear exactly what molecular, cellular, and phenotypic roles Ang2 plays in modeling, and enhanced endothelial cell migration (Lobov et al., 2002) . It is attractive to consider that these same associated postnatal life in normal or pathological vascular processes, and particularly in the setting of cancer.
characteristics might be oppositely affected by Ang2 inhibition. At the molecular level, it remains unclear how Ang2 neutralizaTo begin investigating this question, we generated Ang2-selective peptide-Fc fusion proteins and antibodies, enabling tion affects Tie2 phosphorylation in individual vessels. Attempts to address this question by immunohistochemistry using anticontrolled pharmacological inactivation of endogenous Ang2. This approach to Ang2 inhibition circumvents the neonatal lephospho-Tie2 antibodies have not been successful, as the reagent antibodies generated for this purpose have not been sufthality observed in Ang2 knockout studies and avoids the ambiguous interpretations inherent in studies ficiently sensitive. Evaluating this question in a physiologically relevant setting is critical to elucidating the true biochemical using panangiopoietin inhibitors (Das et al., 2003; Hangai et al., 2001b; Lin et al., 1997 Lin et al., , 1998 Siemeister et al., 1999) . Our studies role of Ang2. A second question that remains to be addressed is whether demonstrate that specific inactivation of endogenous Ang2 inhibits tumor angiogenesis in mice and corneal angiogenesis in selective inhibition of Ang1 would be advantageous or deleterious in terms of efficacy and safety. If, for example, Ang1 and rats, thus establishing that Ang2 plays a proangiogenic role in these processes. A combination of volume-based tumor meaAng2 were both capable of stimulating tumor angiogenesis, then greater tumor growth inhibition might be achievable by surements and histological analysis indicate that selective Ang2 inhibition mediates regression of viable tumor. Moreover, a subneutralizing both angiopoietins, rather than inhibiting Ang2 alone. Alternatively, if Ang1 and Ang2 function in a mutually set ‫)%02ف(‬ of tumor-bearing mice completely responded to long-term anti-Ang2 therapy, in that no residual tumor could be antagonistic manner, then selective Ang1 neutralization might actually stimulate tumor growth. From the standpoint of safety, measured. This result suggested that even established tumor vessels have the capacity to respond to Ang2 inhibition.
one might predict, a priori, that Ang1 inhibition could globally destabilize normal quiescent blood vessels, as Ang1 appears No significant adverse effects were observed in rodents following long-term Ang2 inhibition, despite clear Ang2 expresto play a role in normal vessel maintenance. Systemically administered soluble Tie2 has been reported to be efficacious and sion by ISH in several organs of 10-week-old mice (data not shown). This result is reminiscent of the Ang2 knockout mouse safe in tumor models (Lin et al., 1998), but interpretation of wide applicability in treating human disease. Whether Ang2-16 hr postseeding, the medium was replaced with 100 l per well of fresh selective inhibitors will confer similar activity in humans to that DMEM/10% FBS containing 6.7 M Ang2-neutralizing agents or controls observed in rodent models awaits the introduction of these (all in triplicate). Cells were fixed at 24, 48, 72, 96, and 120 hr post treatment by adding 100 l 10% trichloroacetic acid (TCA). All plates were stored in agents into clinical trials.
10% TCA at 4C and assayed together. The 10% TCA was shaken out, and the wells were rinsed 5 times with water. The cells were then stained with Experimental procedures 100 l of 0.4% sulforhodamine B (Sigma S-9012) in 1% acetic acid (Sigma A-6283) for 10 min at room temperature and then washed 5 times with 1% Angiopoietin:Tie2 neutralization ELISA acetic acid. The plates were then air-dried. The dye was solubilized with 96-well microtiter plates were coated with recombinant angiopoietins in 300 l of 20 mM unbuffered Tris (pH Ͼ 10) for 2 hr on a rotary shaker. 293T cell conditioned media (DMEM/50 g/ml BSA) at 37ЊC for 1 hr. The Optical density (OD) was then read at 540 nm on a microtiter plate reader. conditioned media were used at angiopoietin concentrations that conferred 75% of maximally achievable binding to 1 nM hTie2-Fc (R&D Systems, Tumor cell apoptosis assay catalog #313-TI). Plates were washed with PBS/0.1% Tween-20 and then Tumor cell apoptosis was examined at days 1, 2, and 3 for both 2xCon4 blocked for 2 hr at room temperature with PBS/5% BSA. Peptide-Fc fusion (C)-treated and vehicle-treated controls, from the same study as the Viable proteins and antibodies titrated from 100 nM to 0.4 pM in a solution of PBS/ Tumor Fraction analysis. Sections were stained for cleaved Caspase-3 (Cat#-1% BSA/1 nM Tie2 were added to the angiopoietin-coated plates, which Asp175, Cell Signaling Technologies) using peroxidase localization with DAB were incubated overnight at room temperature and then washed with PBS/ substrate, and a light hematoxylin counterstain. Five widely spaced fields 0.1 percent Tween-20. Mouse-derived anti-Tie2 antibody (Pharmingen Inc., were selected in a blinded fashion from the circumferential region of eight catalog #557039) was added to each plate at a final concentration of 1 tumor sections per group, avoiding the overlying capsule and areas of frank g/ml (1 hr incubation at room temperature), after which plates were washed necrosis. The number of apoptotic tumor cells was counted in each 20ϫ in PBS/0.1% Tween-20. Goat anti-mouse-IgG-HRP (Pierce, catalog #31432) objective field of roughly 135,600 m 2 . was added at a dilution of 1:10,000 in PBS/1% BSA (1 hr incubated at room temperature), after which plates were washed several times with PBS/0.1%
Corneal angiogenesis model Tween-20. TMB substrate (Sigma, catalog #T8665) was added, OD 370 nm Corneal angiogenesis was induced in adult female CD rats weighing absorbance was measured, and degree of angiopoietin:Tie2 neutralization 250-300 g (n ϭ 8 per group) as described (Coxon et al., 2002) . Briefly, 0.6 was determined by comparison against a Tie2 standard curve. mm diameter circular discs of Nyalflo filter paper (Gelman, Ann Arbor, MI) were incubated in PBS containing either 0.1% bovine serum albumin (BSA) VEGF/KDR neutralization ELISA 96-well microtiter plates were coated with recombinant human VEGF (0.1 ml or 0.1% BSA with 10 M vascular endothelial growth factor (VEGF) (R&D Systems, Minneapolis, MN) for 1 hr at 4ЊC. Rats were anesthetized with per well of 5 g/ml hVEGF in PBS/1% BSA) at 37ЊC for 1 hr. The recombinant VEGF was used at concentrations that conferred 80% of maximally achievisoflurane and a single disc was inserted into a pocket in the corneal stroma. The margin of each disc was located ‫8.1ف‬ mm from blood vessels of the able binding to 1 nM human KDR-Fc (R&D Systems, catalog #357-KD/CF). Plates were washed with PBS/0.1% Tween-20 and then blocked for 2 hr lateral limbus. Treatment with 2xCon4 (C) (0, 0.03, 0.1, 0.3, 1.0, or 10 mg/kg), Fc at room temperature with PBS/5% BSA. Peptide-Fc fusion proteins and antibodies titrated from 1000 nM to 0.5 pM in a solution of PBS/1% BSA/ control (70 nM/kg), L1-7(N) (70 nM/kg), or vehicle (PBS) was initiated 1 week prior to corneal implantation and continued twice per week. Rats treated 1 nM KDR-Fc were added to the VEGF-coated plates, which were incubated overnight at room temperature and then washed with PBS/0.1% with Ab536 (Ab536 0.7 or 70 nM/kg) received one injection on the day of surgery and another 3 days later. All treatments were injected subcutaneMouse-derived anti-KDR antibody (R&D Systems, catalog #MAB3573) was added to each plate at a final concentration of 1 g/ml (1 hr incubation at ously. 7 days after surgical implant, the corneas were photographed at 25ϫ room temperature), after which plates were washed in PBS/0.1% Tween-20. Goat anti-mouse-IgG-HRP (Pierce, catalog #31432) was added at a dilution using a Nikon SV-3 Ophthalmic Slit Lamp (Nikon Ophthalmic) equipped with a Nikon D-1 digital camera back. A reference stage micrometer was of 1:5000 in PBS/1% BSA (1 hr incubated at room temperature), after which plates were washed several times with PBS/0.1% Tween-20. TMB substrate photographed for calibration. Numerical data were generated from the digital images using Metamorph image analysis software (v4.5; Universal Imaging, (Sigma, catalog #T8665) was added, OD 370 nm absorbance was measured,
